Q-omics provides the consensus-scored LHX1 profile across patient tissues and cancer cell-line models. LHX1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LHX1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, LHX1 RNA expression shows 10,701 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRC, and TGCT as cancer lineages where LHX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LHX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LHX1 survival associations across molecular data types. LHX1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LHX1 RNA expression–survival associations across cancer types. High LHX1 expression shows unfavorable associations in MESO, KIRP, ACC, HNSC, KIRC and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LHX1 RNA expression.
This table summarizes LHX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LHX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LHX1 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in HNSC, BLCA and LUAD. The KIRC box plot shows higher LHX1 RNA expression in normal versus tumor tissue (log2 FC = −2.891, t-test p < 0.001).
This table shows molecular features associated with LHX1 in patient tissues and cancer cell lines. In patient samples, LHX1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LHX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
